MOUNTAIN VIEW, CA and TOKYO — January 26, 2007 — REGiMMUNE Corporation., a privately held biopharmaceutical company, announced today the appointment of Shirley Liu Clayton as a non-executive director. Ms. Clayton recently retired as President and Chief Executive Officer of Abmaxis, Inc., which was acquired by Merck & Co. in 2006.
As Vice President and Treasurer at Genentech, Inc., the first biopharmaceutical company, Ms. Clayton was actively involved in the early financing of the biotechnology industry. Prior to her role at Abmaxis, she co-founded Raven Biotechnologies, a cell biology company developing monoclonal antibody products, and served as its President and Chief Financial Officer.
“We very much welcome Shirley to the board of REGiMMUNE; her in-depth knowledge and experience in the biotechnology industry will be invaluable to our company as we grow our business in the U.S. and Japan,” commented Haru Morita, President and Chief Executive Officer. “Our lead drug candidates are advancing through preclinical development, with clinical trials planned to begin next year. In addition, we recently established a research and development operation in San Francisco Bay Area, California and are currently filling several key positions for that facility.”
“I am very impressed with the approach REGiMMUNE is taking for its products, which is based on the work of Dr Yasuyuki Ishii, initially at Kirin Pharmaceutical Division and the La Jolla Institute for Allergy & Immunology and now at the RIKEN Research Center for Allergy and Immunology,” stated Shirley Clayton. “REGiMMUNE is fortunate to be able to capitalize on this ground-breaking work and, using immune-regulating technology, develop novel drugs for allergy and autoimmune disease.”
During her 25 years as an executive in the life science industry, Ms. Clayton was Chief Financial Officer, President or Chief Executive Officer in several companies including Protein Design Labs, now PDL BioPharma, Inc.; Cygnus, Inc., a drug delivery company; and CBYON, a medical technology company sold to GE Medical Systems. She is a member of the Board and Audit committee of Metro Bancorp and a member of the Board of Metro United Bank and Chairman of the Credit committee. Ms. Clayton received her MBA from the Stanford University, Graduate School of Business, and her BS in Chemistry from Smith College.
REGiMMUNE is a biotechnology company focused on the discovery, development and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and inflammatory disorders. The company’s proprietary technology platform, reVax (reverse vaccination), works by modulating the immune system by enhancing antigen specific immune regulatory cells. This technique is expected to be useful in conditions such as Ragweed Allergy, Rheumatoid Arthritis (RA) and Multiple Sclerosis (MS), where control of an abnormal immune response is desirable. reVax is being utilized to advance several compounds through clinical development and eventual commercialization of a broad range of products for REGiMMUNE and its partners. The company is headquartered in Tokyo, Japan and has a U.S. subsidiary in Mountain View, California.
US MEDIA CONTACT: